Last reviewed · How we verify
NCT04560972
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
Phase 1 trial testing Atezolizumab in Extensive Stage Lung Small Cell Carcinoma in 3 participants. Participants enrolled and being followed up; not accepting new ones.
27 January 2027
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 28 May 2021 |
| Primary completion | 27 January 2027 |
| Estimated completion | 27 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Atezolizumab (atezolizumab) — full drug profile →
- Carboplatin (Carboplatin) — full drug profile →
- Etoposide (etoposide) — full drug profile →
- Protein Phosphatase 2A Inhibitor LB-100 — full drug profile →
Conditions studied
- Extensive Stage Lung Small Cell Carcinoma — all drugs for Extensive Stage Lung Small Cell Carcinoma →
Sponsor
City of Hope Medical Center
Who can join
18 and older, any sex, with Extensive Stage Lung Small Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase Ib trial studies the side effects and best dose of LB-100 when given together with carboplatin, etoposide, and atezolizumab for the treatment of untreated extensive-stage small cell lung cancer. Drugs such as carboplatin and etoposide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. LB-100 has been shown to make anticancer drugs (chemotherapy) work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A. Blocking this protein makes the tumor cells that express PP2A divide. This allows standard chemotherapy drugs such as carboplatin, etoposide, and atezolizumab work better at killing the tumor cells since these drugs work best at destroying cells that are dividing. Giving LB-100 in combination with standard chemotherapy drugs may work better to treat extensive-stage small cell lung cancer compared to standard chemotherapy drugs alone.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic targeting of "undruggable" MYC.
Llombart V, Mansour MR. · · 2022 · cited 349× · PMID 34942444 · DOI 10.1016/j.ebiom.2021.103756 -
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.
Stanford SM, Bottini N. · · 2023 · cited 80× · PMID 36693907 · DOI 10.1038/s41573-022-00618-w -
PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma.
Mondal I, Das O, Sun R, Gao J, et al · · 2023 · cited 36× · PMID 37219874 · DOI 10.1158/0008-5472.can-22-3382 -
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.
Dias MH, Friskes A, Wang S, Fernandes Neto JM, et al · · 2024 · cited 35× · PMID 38533987 · DOI 10.1158/2159-8290.cd-23-0216 -
Targeting PP2A for cancer therapeutic modulation.
Ronk H, Rosenblum JS, Kung T, Zhuang Z. · · 2022 · cited 35× · PMID 36342229 · DOI 10.20892/j.issn.2095-3941.2022.0330 -
PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen.
Tinsley SL, Allen-Petersen BL. · · 2022 · cited 20× · PMID 35118387 · DOI 10.1093/narcan/zcac002 -
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.
Dias MH, Liudkovska V, Montenegro Navarro J, Giebel L, et al · · 2024 · cited 15× · PMID 38600345 · DOI 10.1038/s44319-024-00128-3 -
Protein phosphatases regulate the liver microenvironment in the development of hepatocellular carcinoma.
Yoon JS, Lee CW. · · 2022 · cited 10× · PMID 36380016 · DOI 10.1038/s12276-022-00883-0
Verify or expand the search:
- PubMed search for NCT04560972
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Atezolizumab
Trials testing the same drug.
- NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
Other recruiting trials for Extensive Stage Lung Small Cell Carcinoma
Currently open trials in the same condition.
- NCT07423585 — Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer · Phase 2 · recruiting
- NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
- NCT06287775 — Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) a · Phase 1, PHASE2 · recruiting
- NCT06110572 — Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation · Phase 1, PHASE2 · recruiting
- NCT05353439 — Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cance · Phase 1 · active not recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04560972 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04560972.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing